This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
View All Zacks #1 Ranked Stocks
Zacks News
Biotech Stock Roundup: Actelion Soars on Acquisition Talks, Another Clinical Hold for Juno
by Arpita Dutt
With Johnson & Johnson eyeing Actelion (ALIOF), will mergers and acquisitions pick pace in the biotech sector?
GW Pharmaceuticals (GWPH): What Awaits in Q4 Earnings?
by Zacks Equity Research
GW Pharmaceuticals (GWPH) is set to report fourth-quarter fiscal 2016 results on Dec 5. The company posted positive surprise of 57.80% in the last quarter.
Lilly/AstraZeneca Expand Alzheimer Disease Collaboration
by Zacks Equity Research
Eli Lilly and Company (LLY) and AstraZeneca plc (AZN) expanded their existing collaboration to develop the second treatment for Alzheimer's disease, MEDI1814
Biogen Presents Positive Early Data from Alzheimer's Study
by Zacks Equity Research
Last week, Biogen Inc. (BIIB) presented positive data from a phase I study (PRIME) on its anti-amyloid treatments in development, aducanumab, at the Clinical Trials on Alzheimer's Disease (CTAD) meeting in San Diego.
Biotech Stock Roundup: Ophthotech Slumps on Fovista Results, Achaogen Skyrockets on Data
by Arpita Dutt
Several companies presented data this week with companies like Achaogen (AKAO) soaring while others like Ophthotech plunged.
Deja Vu for Drug Stocks as Trump Slams Drug Pricing Again
by Arpita Dutt
Drug stocks were hit once again with President-elect Donald Trump's comments about the sector at his first news conference since his election in November.
Pharma Industry Stock Outlook - March 2016
by Arpita Dutt
Looking at consensus earnings expectations, the Medical sector, which had performed well in 2015, is expected to see earnings growth of 0.7% and revenue growth of 7.7% in Q1.
Pharma Industry Stock Outlook - March 2016
by Arpita Dutt
Looking at consensus earnings expectations, the Medical sector, which had performed well in 2015, is expected to see earnings growth of 0.7% and revenue growth of 7.7% in Q1.
Stocks with Upgraded Broker Ratings
by Kevin Matras
Kevin Matras explains why looking for stocks with upgraded broker ratings can upgrade your portfolio to a whole new level. Highlighted stocks include BIIB, LUV, NFG, TOWR and XRS.
by Zacks Equity Research
The biotech segment has been growing well surpassing all expectations.